Myomics is focused on the discovery and screening of compounds to treat neuromuscular disease and minimize muscle adverse effects (as seen with statins).
Myomics seeks to leverage its predictive, human MFAS platform in collaboration with biopharmaceutical partners to accelerate and enhance their drug pipelines.